The healthcare PE landscape in 2026 reflects a market characterized by steady capital deployment, sector maturation and increasingly sophisticated investment strategies across the care continuum.
Portfolio liquidity remains a binding constraint, with average hold periods peaking in 2024 and sponsors increasingly relying on continuation funds and other structures to pace realizations, even as the exit window has begun to reopen for select, high-quality assets.
This white paper surveys more than 20 key subsectors attracting investor attention, identifies emerging themes shaping deal activity, and highlights the structural tailwinds and headwinds that will define the investment environment in the year ahead.
Sectors include:
- General outpatient behavioral health
- Substance use disorder treatment & opioid treatment programs
- Oncology
- Infusion pharmacy
- Post-acute & home-based care
- Musculoskeletal & orthopedics
- Cardiology
- Gastroenterology
- Urology
- Ophthalmology
- Dermatology & med spas
- Dental & dental support organization
- Women’s health
- LGBTQ+ health services
- Ancillary services (ambulatory surgery centers, outpatient imaging & physical/occupational therapy)
- Revenue cycle management & practice management software
- Artificial intelligence
- Specialty pharmacy & pharmacy services
- Market trends in clinical laboratories, laboratory services, & lab developed tests
- Opportunities in FDA approval pathways
- Contract research organizations & site management organizations
- Contract development & manufacturing organizations
Click here to request the white paper.